10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study

BACKGROUND. Vascular endothelial growth factor (VEGF)-targeted agents are standard therapies for metastatic renal cell carcinoma (mRCC), associated with variable tumor shrinkage. Response Evaluation Criteria in Solid Tumors (RECIST) is of limited utility in this setting, and other imaging changes ar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Krajewski, Katherine M., Franchetti, Yoko, Nishino, Mizuki, Fay, André P., Ramaiya, Nikhil, Van den Abbeele, Annick D., Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Genitourinary Cancer: Renal, Bladder, and Testicular
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012965/
https://ncbi.nlm.nih.gov/pubmed/24755461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0391
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados